Seeking Alpha

Aegerion raises Juxtapid sales guidance, shares rise

  • Aegerion Pharmaceuticals (AEGR) impresses with Q2 results, as net sales come in well ahead of expectations.
  • CEO Marc Beer sees "significant room for continued growth as [the company] calibrates activities surrounding the launch of Juxtapid in the U.S."
  • AEGR says 215 patients are currently using Juxtapid — meeting the full year goal of 250-300 patients on therapy looks like a forgone conclusion.
  • FY13 Juxtapid sales forecast is lifted to $30-35M from just $15-25M previously. Shares +15% premarket. (PR)
  • Needham's Chad Messer called it last week.
Comments (2)
  • arthurs1
    , contributor
    Comments (355) | Send Message
    Let's face it, the revenue bar was set real low. Meanwhile they lost more money than expected. But analysts have big egos so that they will ignore.
    30 Jul 2013, 09:29 AM Reply Like
  • Cory Renauer
    , contributor
    Comments (155) | Send Message
    Needham's Chad Messer, last week?!? I called it on June 12!
    And I'll be hanging on way past his $100 price target.
    31 Jul 2013, 01:45 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector